Prevalence and Outcomes of Olfactory and Gustatory Dysfunctions in Patients With COVID-19
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04524754|
Recruitment Status : Unknown
Verified August 2020 by Mohamed Shehata Taha, Ain Shams University.
Recruitment status was: Recruiting
First Posted : August 24, 2020
Last Update Posted : August 28, 2020
Ain Shams University
Information provided by (Responsible Party):
Mohamed Shehata Taha, Ain Shams University
- Study Details
- Tabular View
- Results Submitted
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
|Recruitment Status :||Unknown|
|Estimated Primary Completion Date :||September 11, 2020|
|Estimated Study Completion Date :||November 30, 2020|
|Submission Cycle||Results Submitted to ClinicalTrials.gov||Results Returned after Quality Control Review|
February 18, 2022 ||February 28, 2022|
Moein ST, Hashemian SM, Mansourafshar B, Khorram-Tousi A, Tabarsi P, Doty RL. Smell dysfunction: a biomarker for COVID-19. Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950. doi: 10.1002/alr.22587. Epub 2020 Jun 18.